Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSV-B preF protein
- Development stage
- Unknown
- Lead developer
- Janssen Pharmaceutical
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
RSV-B preF protein (JNJ-78991172) is a recombinant protein subunit vaccine antigen developed by Janssen Vaccines & Prevention B.V. (a Johnson & Johnson company). It consists of a prefusion conformation-stabilized fusion (F) protein derived from the respiratory syncytial virus (RSV) B subtype. The F protein is a critical target for neutralizing antibodies, and stabilizing it in its prefusion state is intended to elicit a more potent and protective immune response compared to postfusion forms. This antigen is being investigated as a component of next-generation multivalent RSV vaccine candidates, often evaluated in combination with adenovirus-vectored components (such as Ad26.RSV.preF) or RSV A subtype antigens. Clinical development has focused on preventing RSV-mediated lower respiratory tract disease (LRTD) in older adults, with Phase 1/2a trials (e.g., NCT05327816) assessing its safety and immunogenicity.
- Other names
- RSV B subtype prefusion F proteinRSV.preF protein
02
Targets
RSV preF (Respiratory syncytial virus prefusion F glycoprotein)
Beyond the preview
Go deeper on RSV-B preF protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSV-B preF protein.